EFFICACY AND SAFETY OF SOFOSBUVIR/ VELPATASVIR WITH OR WITHOUT RIBAVIRIN IN HCV- INFECTED CHINESE PATIENTS: A PROSPECTIVE COHORT STUDY

被引：0
|
作者：
Wang, Jiayi [1 ]
Du, Lingyao [1 ]
Zhou, Chen [1 ]
Zeng, Yilan [2 ]
Chen, Enqiang [1 ]
Zhang, Dong-Mei [1 ]
Cheng, Xing [1 ]
Song, Xiaona [1 ]
Han, Ning [1 ]
Liu, Miao [1 ]
Chen, Han [1 ]
Tang, Hong [1 ]
机构：
[1] Sichuan Univ, West China Hosp, Div Infect Dis, Ctr Infect Dis,State Key Lab Biotherapy, Chengdu 610041, Sichuan, Peoples R China
[2] Publ Hlth Clin Ctr Chengdu, Chengdu 610041, Sichuan, Peoples R China
来源：
HEPATOLOGY | 2023年 / 78卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1868A
引用
收藏
页码：S718 / S719
页数：2
相关论文
共 50 条
  • [31] Safety and Efficacy of Sofosbuvir/Velpatasvir in Genotype 1-6 HCV-Infected Patients in China: Results from a Phase 3 Clinical Trial
    Wei, Lai
    Xie, Qing
    Huang, Yan
    Wu, Shanming
    Xu, Min
    Tang, Hong
    Cheng, Jun
    Gao, Yanhang
    Mou, Zhuangbo
    Dou, Xiaoguang
    Nan, Yuemin
    Ning, Qin
    Mao, Yimin
    Stamm, Luisa
    Lu, Sophia
    Dvory-Sobol, Hadas
    Mo, Hongmei
    Brainard, Diana
    Yang, Yongfeng
    Wang, Guiqiang
    Hu, Peng
    Zhang, Lunli
    Gao, Zhiliang
    Lin, Feng
    Shang, Jia
    Gong, Guozhong
    Li, Jun
    Su, Minghua
    Duan, Zhongping
    Hou, Jinlin
    Jia, Jidong
    HEPATOLOGY, 2018, 68 : 379A - 379A
  • [32] EFFICACY AND SAFETY OF 12-WEEK SOFOSBUVIR/VELPATASVIR THERAPY IN CHRONIC HEPATITIS C PATIENTS WITH DIFFERENT HCV GENOTYPES INFECTION: A PROSPECTIVE STUDY FROM THE REAL WORLD
    Chen, Enqiang
    Zhang, Dong-Mei
    Liu, Miao
    Tang, Hong
    HEPATOLOGY, 2022, 76 : S375 - S376
  • [33] EFFICACY AND SAFETY OF ADDING RIBAVIRIN FOR GENOTYPE 3 HCV COMPENSATED CIRRHOSIS RECEIVING 12-WEEKS OF SOFOSBUVIR/VELPATASVIR: A META-ANALYSIS
    Loo, Jing Hong
    Xu, Wen Xin Flora
    Low, Gerald J.
    Tay, Wei Xuan
    Ang, Le Shaun
    Tam, Yew Chong
    Kumar, Rahul
    Wong, Yu Jun
    GASTROENTEROLOGY, 2022, 162 (07) : S1281 - S1281
  • [34] Integrated Safety Analysis of Daclatasvir Plus Sofosbuvir, With or Without Ribavirin, in Patients With HCV Genotype 3 Infection
    Bernstein, David
    Landis, Charles S.
    Lawitz, Eric
    Luetkemeyer, Anne
    Harris, Melissa
    Bhore, Rafia
    Swenson, Eugene S.
    Ackerman, Peter
    Rana, Khurram
    Dieterich, Douglas
    HEPATOLOGY, 2015, 62 : 571A - 571A
  • [35] Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosis
    Ogawa, Eiichi
    Furusyo, Norihiro
    Nomura, Hideyuki
    Takahashi, Kazuhiro
    Higashi, Nobuhiko
    Kawano, Akira
    Dohmen, Kazufumi
    Satoh, Takeaki
    Azuma, Koichi
    Nakamuta, Makoto
    Koyanagi, Toshimasa.
    Kato, Masaki
    Shimoda, Shinji
    Kajiwara, Eiji
    Hayashi, Jun
    ANTIVIRAL RESEARCH, 2016, 136 : 37 - 44
  • [36] SAFETY AND EFFICACY OF SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR-BASED REGIMENS FOR THE TREATMENT OF HCV GENOTYPE 1-6: RESULTS OF THE HCV-TARGET COHORT
    Zeuzem, Stefan
    Sulkowski, Mark S.
    Lim, Joseph K.
    Morelli, Giuseppi
    Khalili, Mandana
    Brown, Robert S., Jr.
    Ben-Ari, Ziv
    Park, James S.
    Reddy, K. Rajender
    Shiffman, Mitchell L.
    Dong, Meichen
    Vainorius, Monika
    Fried, Michael W.
    Nelson, David R.
    Terrault, Norah
    HEPATOLOGY, 2019, 70 : 939A - 940A
  • [37] Efficacy of Ledipasvir and Sofosbuvir, With or Without Ribavirin, for 12 Weeks in Patients With HCV Genotype 3 or 6 Infection
    Gane, Edward J.
    Hyland, Robert H.
    An, Di
    Svarovskaia, Evguenia
    Pang, Phillip S.
    Brainard, Diana
    Stedman, Catherine A.
    GASTROENTEROLOGY, 2015, 149 (06) : 1454 - +
  • [38] EXCELLENT EFFICACY AND SAFETY OF SOFOSBUVIR, GLECAPREVIR, PIBRENTASVIR AND RIBAVIRIN FOR RETREATMENT OF CHRONIC HEPATITIS C AFTER SOFOSBUVIR, VELPATASVIR AND VOXILAPREVIR FAILURE
    Saxena, Varun
    McKinney, Jeff
    Chamberland, Scott
    Catalli, Lisa
    Seo, Suk
    Ready, Joanna B.
    Price, Jennifer C.
    HEPATOLOGY, 2021, 74 : 66A - 67A
  • [39] HIGH EFFICACY OF SOFOSBUVIR/VELPATASVIR/GS-9857 WITH OR WITHOUT RIBAVIRIN FOR 12 WEEKS IN DIRECT ACTING ANTIVIRAL-EXPERIENCED PATIENTS WITH GENOTYPE 1 HCV INFECTION
    Lawitz, E.
    Poordad, F.
    Wells, J.
    Hyland, R. H.
    Yang, Y.
    Dvory-Sobol, H.
    Stamm, L. M.
    Brainard, D. M.
    McHutchison, J. G.
    Landaverde, C.
    Gutierrez, J.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S146 - S146
  • [40] Safety and efficacy of sofosbuvir plus velpatasvir with or without ribavirin for chronic hepatitis C virus infection: A systematic review and meta-analysis
    Ahmed, Hussien
    Abushouk, Abdelrahman I.
    Attia, Attia
    Gadelkarim, Mohamed
    Gabr, Mohamed
    Negida, Ahmed
    Abdel-Daim, Mohamed M.
    JOURNAL OF INFECTION AND PUBLIC HEALTH, 2018, 11 (02) : 156 - 164
12345